RxDoctor Payments Data

Debra Perkins

Family · Kokomo, INNPI 1073842563

Payments from drug & device makers

$722in general payments, 2019–2025

Across 41 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • AstraZeneca$86
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$75
  • Amgen$68
  • Sanofi Pasteur Inc.$43
  • Corium, LLC$39
  • plus $239 from 11 others

What the payments were for

  • Food & beverage$722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$722 in reported general payments places this provider in the 60th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$1,038
Medicare patients
54
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$78,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$45,690
JardianceEmpagliflozin25$21,031
MounjaroTirzepatide15$17,704
Breo ElliptaFluticasone/Vilanterol41$17,252
Tresiba Flextouch U-200Insulin Degludec12$16,077
TrulicityDulaglutide14$13,405
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$9,903
VyvanseLisdexamfetamine Dimesylate12$5,308
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,863
Albuterol Sulfate HfaAlbuterol Sulfate112$2,772
Omeprazole158$1,942
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$1,921
Duloxetine Hcl80$1,912
Buspirone Hcl83$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$78,84756 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$32$72,84598 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,392 family providers in Indiana.

Other family in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →